AR003140A1 - Nuevos compuestos utiles para inhibir las interacciones de las tirosinaquinasas/proteinas adaptadoras, composiciones farmaceuticas que lascontienen y metodos de aplicacion de dichos compuestos para inhibir dichas interacciones. - Google Patents

Nuevos compuestos utiles para inhibir las interacciones de las tirosinaquinasas/proteinas adaptadoras, composiciones farmaceuticas que lascontienen y metodos de aplicacion de dichos compuestos para inhibir dichas interacciones.

Info

Publication number
AR003140A1
AR003140A1 ARP960103099A AR10309996A AR003140A1 AR 003140 A1 AR003140 A1 AR 003140A1 AR P960103099 A ARP960103099 A AR P960103099A AR 10309996 A AR10309996 A AR 10309996A AR 003140 A1 AR003140 A1 AR 003140A1
Authority
AR
Argentina
Prior art keywords
compounds
inhibit
interactions
pharmaceutical compositions
methods
Prior art date
Application number
ARP960103099A
Other languages
English (en)
Spanish (es)
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of AR003140A1 publication Critical patent/AR003140A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP960103099A 1995-06-07 1996-06-11 Nuevos compuestos utiles para inhibir las interacciones de las tirosinaquinasas/proteinas adaptadoras, composiciones farmaceuticas que lascontienen y metodos de aplicacion de dichos compuestos para inhibir dichas interacciones. AR003140A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47613695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
AR003140A1 true AR003140A1 (es) 1998-07-08

Family

ID=23890650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103099A AR003140A1 (es) 1995-06-07 1996-06-11 Nuevos compuestos utiles para inhibir las interacciones de las tirosinaquinasas/proteinas adaptadoras, composiciones farmaceuticas que lascontienen y metodos de aplicacion de dichos compuestos para inhibir dichas interacciones.

Country Status (11)

Country Link
US (4) US5780496A (enExample)
EP (1) EP0831809A4 (enExample)
JP (1) JPH11506770A (enExample)
KR (1) KR19990022369A (enExample)
CN (1) CN1192680A (enExample)
AR (1) AR003140A1 (enExample)
BR (1) BR9609353A (enExample)
CA (1) CA2224103A1 (enExample)
IL (1) IL122427A0 (enExample)
MX (1) MX9709442A (enExample)
WO (1) WO1996040115A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
CA2050057A1 (en) 1991-03-04 1992-09-05 Adam Heller Interferant eliminating biosensors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
US6376529B1 (en) 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
EP0944720A1 (en) 1996-12-03 1999-09-29 Sugen, Inc. Adaptor protein frs2 and related products and methods
US6051597A (en) * 1997-06-13 2000-04-18 Merck & Co., Inc. Indolylquinones as antidiabetic agents
CA2321307A1 (en) 1998-02-27 1999-09-02 Venkatachala L. Narayanan Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US6077849A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antidiabetic agents
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) * 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) * 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
WO2000056760A1 (en) * 1999-03-23 2000-09-28 The United States Of America, Represented By Secretary, Department Of Health And Human Services Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
WO2001028577A2 (en) 1999-10-22 2001-04-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US6165728A (en) * 1999-11-19 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of NCK-2 expression
CA2419870A1 (en) * 2000-08-22 2002-02-28 Yang Gao Sh2 domain binding inhibitors
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7151162B2 (en) * 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
US7057052B2 (en) 2002-09-26 2006-06-06 Duke University Heterocyclic quinones as pharmaceutical agents
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc CONTINUOUS BLOOD SUGAR MONITORING SYSTEM AND USE METHOD
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US8600920B2 (en) * 2003-11-28 2013-12-03 World Assets Consulting Ag, Llc Affinity propagation in adaptive network-based systems
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
JP2008532926A (ja) * 2004-12-06 2008-08-21 アバンテイス・フアルマ・エス・アー 置換インドール化合物、それを含有する組成物、この製造方法およびこの使用
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
NZ601635A (en) * 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US9912758B2 (en) 2014-12-16 2018-03-06 Yahoo Holdings, Inc. Continuing an application session on a different device
CN120365272A (zh) 2018-10-05 2025-07-25 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917820A (en) * 1969-05-29 1975-11-04 Canadian Patents Dev Antibiotic cochliodinol and production by chaetomium, cochliodes and chaetomium globsum
JPH0236591B2 (ja) * 1979-08-27 1990-08-17 Kyoto Pharma Ind Kinonjudotai
JPS6191167A (ja) * 1984-10-08 1986-05-09 Kyoto Yakuhin Kogyo Kk キノン誘導体
JPS6360966A (ja) * 1986-08-29 1988-03-17 Kyoto Yakuhin Kogyo Kk キノン誘導体
SE8903455D0 (sv) * 1989-10-19 1989-10-19 Joakim Nelson Dynamiska digitala foerbindelsenaet (dfn)
US5469431A (en) * 1993-07-12 1995-11-21 Philips Electronics North America Corp. Method of and apparatus for channel mapping with relative service identification
DE4329010A1 (de) * 1993-08-28 1995-03-02 Sel Alcatel Ag Funksystem
US6205143B1 (en) * 1996-03-14 2001-03-20 Telefonaktiebolaget L M Ericsson System supporting variable bandwidth asynchronous transfer mode network access for wireline and wireless communications
US5841777A (en) * 1996-08-30 1998-11-24 Hewlett-Packard Company System and method for accommodating ABR and CBR traffic on a shared communications channel
US6363058B1 (en) * 1997-09-24 2002-03-26 Telefonaktiebolaget L M Ericsson (Publ) Multi-service handling by a single mobile station
FI980293A7 (fi) * 1998-02-09 1999-08-10 Nokia Corp Multimedia- ja monipalvelupuhelut matkaviestinverkossa
CN1284243A (zh) * 1998-11-30 2001-02-14 诺基亚网络有限公司 空中接口容量调度方法

Also Published As

Publication number Publication date
IL122427A0 (en) 1998-06-15
WO1996040115A1 (en) 1996-12-19
CA2224103A1 (en) 1996-12-19
US20020016353A1 (en) 2002-02-07
US6239161B1 (en) 2001-05-29
BR9609353A (pt) 1999-05-11
JPH11506770A (ja) 1999-06-15
CN1192680A (zh) 1998-09-09
EP0831809A1 (en) 1998-04-01
MX9709442A (es) 1998-02-28
KR19990022369A (ko) 1999-03-25
AU5979996A (en) 1996-12-30
EP0831809A4 (en) 2001-11-28
US5780496A (en) 1998-07-14
AU697120B2 (en) 1998-09-24
US6090838A (en) 2000-07-18

Similar Documents

Publication Publication Date Title
AR003140A1 (es) Nuevos compuestos utiles para inhibir las interacciones de las tirosinaquinasas/proteinas adaptadoras, composiciones farmaceuticas que lascontienen y metodos de aplicacion de dichos compuestos para inhibir dichas interacciones.
YU70494A (sh) Inhibitori proteinske kinaze c
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
MX9707431A (es) Inhibidores de la proteina cinasa c.
ID27124A (id) Penghambat kinase bisiklik
HUP0103520A2 (hu) Protein tirozin kinázokat gátló hatású szubsztituált 3-cianokinolinok és ezeket tartalmazó gyógyászati készítmények
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
MY133159A (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
HUP0104752A3 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors and pharmaceutical compositions containing them
AU2464601A (en) Tricyclic protein kinase inhibitors
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
FI941964A7 (fi) Pitkäketjuiset alfa-asetyleenialkoholit hydrosilylointireaktion estoaineina ja niiden käyttäminen stabiilien, kovettuvien silikonikoostumusten valmistukseen
BR9806296B1 (pt) compostos de ácido sulfìnico, mistura, composição e uso dos mesmos.
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
DE60007095T2 (de) Calanolide zur hemmung von btk
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
AU3040300A (en) Fluorescent dyes for solid phase and solution phase screening
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors